Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain

Joint Bone Spine

Volumn 70, Issue 3, 2003, Pages 219-225

  Goupille, Philippe ^a   Logeart, Isabelle ^b   Combe, Bernard ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b Laboratoire MSD   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Coxibs; Gastrointestinal safety; Musculoskeletal pain; NSAIDs; Survey

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOPROFEN; NABUMETONE; NAPROXEN; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; TENOXICAM;

ADULT; ARTICLE; BONE PAIN; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; FRANCE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; RISK BENEFIT ANALYSIS; STOMACH PAIN; TREATMENT OUTCOME;

EID: 0038677947     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(03)00047-2     Document Type: Article

References (27)

1. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Members of the ACR subcommittee on osteoarthritis guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee-2000 Update. Arthritis Rheum 2000;43:1905-15.
2. Pendleton A, Arden N, Dougados M, et al. Eular recommendations for the management of knee osteoarthritis. Report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Annu Rheum Dis 2000;59:936-44.
3. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587-98.
4. Moskowitz RW. Osteoarthritis: simple analgesics versus nonsteroidal antiinflammatory drugs. J Rheumatol 2001;28:932-4.
5. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee. A randomized trial. JAMA 2002;287:64-71.
6. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatorydrugs over acetaminophen by rheumatic disease patients. Arthritis Rheum 2000;43:378-85.
7. Bjorkman D. Non steroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract and esophagus. Am J Med 1998;105:17-21.
8. Cochran WG. Sampling techniques. 3rd ed. New York: J. Wiley; 1977.
9. Grosbras JM. Méthode statistique des sondages. Paris: Economica; 1987.
10. Ardilly P. Les techniques de sondage. Paris: Technip; 1994.
11. Harris Jr ED. The bone and joint decade. A catalyst of progress. Arthritis Rheum 2001;44:1969-70.
12. Wolfe MM, Lichtensteil DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340: 1888-9.
13. Singh G, Ramey DR, Morfeld D, Shi H, Hatoun HT, Fries JF. Gastrointestinal tract complications of nonsteroidal antiinflammatorydrug treatment in rheumatoid arthritis. Arch Intern Med 1996;156:1530-7.
14. Larkai EN, Smith JL, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal antiinflammatory drugs use. Am J Gastroenterol 1987;82:1153-8.
15. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus Diclofenac in long term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999;354:2106-11.
16. Simon LS, Weaver AL, Graham DY, Kivitz A, Lipsky PE, Hubbard RC, et al. Anti-inflammatoryand upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
17. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7.
18. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastro-intestinal complications. J Rheumatol 1999;26:18-24.
19. Tramer MR, Moore RA, Reynolds DJ, Mc Quay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85:169-82.
20. Berthelot JM, Millet S, Chatelier B, Ripoll N, Maugars Y, Prost A. Connaissance par 125 patients des règles de prise de leur antiinflammatoire non stéroïdien. Thérapie 1999;54:683-8.
21. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-5.
22. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
23. Silverstein FE, Faich G, Golstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
24. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davies B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
25. Harper S, Lee M, Curtis S, Ng J, Watson DJ, Bolognese J. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001;44(Suppl):S318 [abstract].
26. Lipsky P, Abramson SB, Breedveld FC, Brook P, Burmester R, Buttgereit F, et al. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheum 2000;27:1338-40.
27. Combe B, Schaeverbeke T, Sibilia J. Coxibs: ne nous trompons pas de combat. La Lettre du Rhumatologue 2001;275:3-5.